Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging
about
Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR ImagingAdvanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade gliomaModern brain tumor imagingPermeability imaging in pediatric brain tumors.Perfusion MRI: the five most frequently asked clinical questions.Functional imaging in adult and paediatric brain tumours.Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis.Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.Advanced MR imaging of gliomas: an updateThe role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging.Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity.Pros and cons of current brain tumor imagingPrognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaginBenefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging OptionsTumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients.Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imagingPerfusion CT imaging of brain tumors: an overview.Advances in MRI assessment of gliomas and response to anti-VEGF therapy.[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.Clinical applications of dynamic susceptibility contrast perfusion-weighted MR imaging in brain tumours.Glioblastoma biomarkers from bench to bedside: advances and challenges.[Visualization of radiation effects on the central nervous system].Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).Neuroimaging findings of the post-treatment effects of radiation and chemotherapy of malignant primary glial neoplasmsSurvival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors.Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?Toward distinguishing recurrent tumor from radiation necrosis: DWI and MTC in a Gamma Knife--irradiated mouse glioma model.Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications.Effect of contrast leakage on the detection of abnormal brain tumor vasculature in high-grade glioma.The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard
P2860
Q26796223-AC62EAFD-7D83-4ACA-A57E-3015B4EB26FFQ26826862-6334EF82-2534-485C-BBE2-14C322E70904Q27002344-510EBB92-D482-4E5E-8F39-A920FE1842ECQ30392559-3C4E2886-E792-40E0-96D5-E42A066BDB2FQ30416198-B9D251E4-370B-4112-8111-07A13F515451Q30577397-44A74EF0-E267-4B77-9911-5B5078726CBCQ30579847-C9ECF4F3-B53E-47AE-A6A2-DBB5DD9CFA01Q30582849-3F30D579-AF80-46FE-A944-1228B2469113Q30617625-64F3A2BE-362E-40E3-B8CF-B8D0D149A863Q30653828-233F6590-EEA2-40B5-AF28-F3B55B06B667Q30655700-B322F68C-E241-4444-AFE6-6F92819A6B62Q30797166-B109439D-F787-42B7-8156-056319248CFBQ30818733-73083E05-6004-4B5D-A2C6-569DA58735D6Q30832828-9A20CC56-72C3-4856-8D27-10536EF98FF1Q30860126-C1C8AADA-BD7F-4B0F-BC39-BB0EDC58A477Q30871297-00455FD7-FDA3-47E1-8D76-CB6A35596742Q30872679-34060E7A-814F-45F3-8C5C-876A930C14E3Q30907831-3E023DE4-545F-4FEC-9BA7-54B80AB1BB79Q30930526-2F1B71F1-1E75-494D-A174-C08537CFC316Q30938805-46901DAE-EDB0-4D63-827E-4F7E8A167905Q30988706-FEBA174A-476B-4737-8877-2CA48A2714C1Q30998509-FB11153D-DD95-4EF6-BB60-A043AC1AC803Q33525779-4045ACCD-2004-4BC0-927D-318779FE2510Q33738599-C968898B-A116-4D76-B437-343A27A483AFQ33793253-D505636B-A1FC-44B0-AF30-74A5C648A988Q33818313-3B52ECC9-DBB6-4EB9-9759-0CD070FBB502Q33888366-0F78589D-B925-4A40-B6FE-BC95DE93AF78Q34011150-C43BE70F-6F1A-485C-942B-FA3AD33A8BC0Q34103890-AC5642C8-51BC-4B82-9101-E6A72B512B05Q34220560-41CEE5BB-EDE8-42BD-9539-B4835B4E0FF1Q34331320-47CC3185-5F9C-4024-B12F-ACC734FFEDA2Q34369465-83C4CAEF-69C0-4842-8731-4DA85349C5FEQ34389144-EE82B22B-5D3D-4271-9A13-14C259603098Q34517492-DB102151-CB38-455E-B345-1CEC7312308EQ34560322-D7959153-D047-44F9-83BA-176D7801C862Q35018782-39D367C3-DAA3-4E38-BD25-B8D4D0303742Q35035576-00F4E2D9-F6DB-45FC-8FB2-E3E1301FF175Q35047706-0E8713EB-0D99-4EE3-B1DC-5AE5CFF08DFCQ35047716-B3A25075-E488-43A2-B2E8-09F1B71997C2Q35090720-52EE9F28-8EFF-425B-8A23-AA0D52ECF6A2
P2860
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Differentiation of recurrent g ...... -enhanced perfusion MR imaging
@ast
Differentiation of recurrent g ...... -enhanced perfusion MR imaging
@en
type
label
Differentiation of recurrent g ...... -enhanced perfusion MR imaging
@ast
Differentiation of recurrent g ...... -enhanced perfusion MR imaging
@en
prefLabel
Differentiation of recurrent g ...... -enhanced perfusion MR imaging
@ast
Differentiation of recurrent g ...... -enhanced perfusion MR imaging
@en
P2093
P2860
P1433
P1476
Differentiation of recurrent g ...... -enhanced perfusion MR imaging
@en
P2093
Andrew T Parsa
Jamie S Chang
Mark R Segal
Michael W McDermott
Mitchel S Berger
Ramon F Barajas
Soonmee Cha
P2860
P304
P356
10.1148/RADIOL.2532090007
P407
P577
2009-09-29T00:00:00Z